Skip to content
  • Publications
  • Training
  • FAQs
  • M&E Dashboard
  • Vacancies
Menu
  • Publications
  • Training
  • FAQs
  • M&E Dashboard
  • Vacancies
Contact
  • COVID-19
    • SARS-COV-2 Rapid Test Reporting
    • TrakCare Lab Webview
    • COVID-19 Frequently Asked Questions
    • COVID-19 Returning to Work FAQs
    • COVID-19 Surveillance Reports
    • COVID-19 Vaccine
    • Variant Tracking in South Africa
    • COVID-19 Technical Resources
    • COVID-19 Guidelines
    • COVID-19 Advice for The Public
    • COVID-19 Prevention
    • COVID-19 Advice for Travellers
    • Long COVID
    • COVID-19 Vaccine Breakthrough Cases Frequently Asked Questions
    • COVID-19 Resources for Children
    • COVID-19 Communication Resources
    • COVID-19 Contact Resources
  • About Us
    • Overview
    • Our Objectives
    • Management
    • Our Partners
    • Data protection and privacy policy
  • Centres
    • Centre for Emerging Zoonotic and Parasitic Diseases
    • Centre for Enteric Diseases
    • Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses
    • Centre for HIV and STIs
    • Centre for Respiratory Diseases and Meningitis
    • Centre for Tuberculosis
    • Centre for Vaccines and Immunology
    • Division of Public Health, Surveillance and Response
    • National Cancer Registry
      • Cancer Statistics
    • Transversal Functions
  • Our Services
    • Surveillance
    • Training
    • Outbreak Response
    • Research
    • Proficiency Testing Schemes
    • Diagnostic Services
  • Notifiable Medical Conditions
    • Overview
    • Notification Process
    • Tutorial Videos
    • Notification Forms
    • NMC COVID-19 Documents
    • Contacts
  • Media
    • Alerts
    • News
    • Videos
    • Podcasts
    • Blogs
Menu
  • COVID-19
    • SARS-COV-2 Rapid Test Reporting
    • TrakCare Lab Webview
    • COVID-19 Frequently Asked Questions
    • COVID-19 Returning to Work FAQs
    • COVID-19 Surveillance Reports
    • COVID-19 Vaccine
    • Variant Tracking in South Africa
    • COVID-19 Technical Resources
    • COVID-19 Guidelines
    • COVID-19 Advice for The Public
    • COVID-19 Prevention
    • COVID-19 Advice for Travellers
    • Long COVID
    • COVID-19 Vaccine Breakthrough Cases Frequently Asked Questions
    • COVID-19 Resources for Children
    • COVID-19 Communication Resources
    • COVID-19 Contact Resources
  • About Us
    • Overview
    • Our Objectives
    • Management
    • Our Partners
    • Data protection and privacy policy
  • Centres
    • Centre for Emerging Zoonotic and Parasitic Diseases
    • Centre for Enteric Diseases
    • Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses
    • Centre for HIV and STIs
    • Centre for Respiratory Diseases and Meningitis
    • Centre for Tuberculosis
    • Centre for Vaccines and Immunology
    • Division of Public Health, Surveillance and Response
    • National Cancer Registry
      • Cancer Statistics
    • Transversal Functions
  • Our Services
    • Surveillance
    • Training
    • Outbreak Response
    • Research
    • Proficiency Testing Schemes
    • Diagnostic Services
  • Notifiable Medical Conditions
    • Overview
    • Notification Process
    • Tutorial Videos
    • Notification Forms
    • NMC COVID-19 Documents
    • Contacts
  • Media
    • Alerts
    • News
    • Videos
    • Podcasts
    • Blogs
Search
Close
Search
Close
  • OVERVIEW
  • OUR OBJECTIVES
  • MANAGEMENT
  • OUR PARTNERS
  • DATA PROTECTION AND PRIVACY POLICY
Menu
  • OVERVIEW
  • OUR OBJECTIVES
  • MANAGEMENT
  • OUR PARTNERS
  • DATA PROTECTION AND PRIVACY POLICY

Haemophilus Influenzae type B

Diseases A-Z Index Haemophilus Influenzae type B

Diseases A-Z Index:
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • W
  • V
  • X
  • Y
  • Z

What is Haemophilus influenzae type B? 

Haemophilus influenza type b (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in children aged less than 5 years. It is transmitted through the respiratory tract from infected to susceptible individuals. Hib also causes potentially severe inflammatory infections of the face, mouth, blood, epiglottis, joints, heart, bones, peritoneum, and trachea. Although this problem occurs worldwide the burden of Hib disease was considerably higher in resource-poor countries, prior to the introduction of the vaccine into their national immunization programmes.

Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. Hib vaccines are safe and efficacious even when administered in early infancy. In view of their demonstrated safety and efficacy, WHO recommends that Hib conjugate vaccines to be included in all routine infant immunization programmes. This website provides the latest summary information available to WHO about progress with decision-making and implementation of Hib vaccine introduction. It also presents estimates of disease burden reduction and indicators of programmatic implementation, including the development of surveillance networks to monitor progress at country level, and types of products used.

HAEMOPHILUS INFLUENZAE FAQ (2018)
CASE DEFINITION FORM (2021)

All specimens that are sent to the Centre for Respiratory Diseases and Meningitis for diagnostic testing are submitted together with a specimen submission form.

SPECIMEN SUBMISSION FORM

Share

Share on facebook
Share on twitter
Facebook Instagram Linkedin Twitter Youtube

Quick Links

  • M&E Dashboard
  • Publications
  • Vacancies
  • Researcher Directory
  • Terms and Conditions

Download NMC

  • Android App
  • Huawei App
  • Web Portal
  • Apple App

Connect with our Researchers

Contact Us

© NICD 2021. All Rights Reserved
Disclaimer: The National Institute for Communicable Diseases does not provide Medical Advice to the public. For Medical Advice, please consult your Healthcare provider.